Sar studies on carboxylic acid series m1 selective positive allosteric modulators (Pams)

Current Topics in Medicinal Chemistry

Volumn 14, Issue 15, 2014, Pages 1738-1754

  Kuduk, Scott D ^a   Beshore, Douglas C ^a  

^a MERCK RESEARCH LABORATORIES   (United States)

Author keywords

Allosteric; Alzheimer s; BQCA; Modulator; Muscarinic; Positive; Quinolone

Indexed keywords

ACETYLCHOLINE; BENZYL QUINOLONE CARBOXYLIC ACID; CARBOXYLIC ACID DERIVATIVE; FLUORINE; MUSCARINIC M1 RECEPTOR; MUSCARINIC M1 RECEPTOR AGONIST; PIPERIDINE; QUINOLONE; UNCLASSIFIED DRUG; CARBOXYLIC ACID; MOLECULAR LIBRARY; MUSCARINIC AGENT; QUINOLONE DERIVATIVE;

ALLOSTERISM; ALZHEIMER DISEASE; ARTICLE; BINDING AFFINITY; BLOOD BRAIN BARRIER; CELL MEMBRANE PERMEABILITY; CENTRAL NERVOUS SYSTEM; CHOLINERGIC SYSTEM; CONCENTRATION (PARAMETERS); DRUG BINDING SITE; DRUG CLEARANCE; DRUG HALF LIFE; DRUG MECHANISM; DRUG POTENTIATION; DRUG PROTEIN BINDING; DRUG STRUCTURE; DRUG SYNTHESIS; EPISODIC MEMORY; HUMAN; LIPOPHILICITY; NONHUMAN; REACTION OPTIMIZATION; STRUCTURE ACTIVITY RELATION; SUBSTITUTION REACTION; AGONISTS; ANIMAL; BINDING SITE; CHEMISTRY; COGNITION; DISEASE MODEL; DRUG EFFECTS; ENZYME SPECIFICITY; MOLECULAR LIBRARY; MOUSE; PATHOPHYSIOLOGY; PHARMACOLOGY;

ALLOSTERIC REGULATION; ALLOSTERIC SITE; ALZHEIMER DISEASE; ANIMALS; CARBOXYLIC ACIDS; COGNITION; DISEASE MODELS, ANIMAL; HUMANS; MICE; MUSCARINIC AGONISTS; QUINOLONES; RECEPTOR, MUSCARINIC M1; SMALL MOLECULE LIBRARIES; STRUCTURE-ACTIVITY RELATIONSHIP; SUBSTRATE SPECIFICITY;

EID: 84925943659     PISSN: 15680266     EISSN: 18734294     Source Type: Journal    
DOI: 10.2174/1568026614666140826120224     Document Type: Article

References (49)

1. Geula, C. Abnormalities of neural circuitry in Alzheimer's disease: hippocampus and cortical innervation. Neurology, 1998, 51, S18-29.
2. Hansen, R.A.; Gartlehner, G.; Webb, A.P.; Morgan, L.C.; Moore, C.G.; Jonas, D.E. Efficacy and safety of donepezil, galantamine, and rivastigmine for the treatment of Alzheimer’s disease: A systematic review and meta-analysis. Clin. Interv. Aging, 2008, 3, 211–225
3. Giacobini, E. Cholinesterase inhibitors stabilize Alzheimer’s disease. Ann. NY. Acad. Sci., 2000, 920, 321-327.
4. Bonner, T.I. The molecular basis of muscarinic receptor diversity. Trends Neurosci., 1989, 12, 148-151.
5. Bonner, T.I. New subtypes of muscarinic acetylcholine receptors. Trends Pharmacol Sci., 1989, 11-15.
6. Bymaster, F.P.; McKinzie, D.L.; Felder, C.C.; Wess, J. use of M1-M5 muscarinic receptor knockout mice as novel tools to delineate the physiological roles of the muscarinic cholinergic system. Neurochem. Res., 2003, 28, 43-442.
7. Wess, J.; Eglen, R.M.; Gautam D Muscarinic acetylcholine receptors: mutant mice provide new insights for drug development. Nat.Rev. Drug Discov, 2007, 6, 721-733.
8. Langmead, C.J.; Watson, J.; Reavill, C. Muscarinic acetylcholine receptors as CNS drug targets. Pharmacol. Ther., 2008, 117, 232-243.
9. Greenlee, W.; Clader, J.; Asbersom, T.; McCombie, S.; Ford, J.; Guzik, H.; Kozlowski, J.; Li, S.; Liu, C.; Lowe, D.; Vice, S.; Zhao, H.; Zhou, G.; Billard, W.; Binch, H.; Crosby, R.; Duffy, R.; Lachowicz, J.; Coffin, V.; Watkins, R.; Ruperto, V.; Strader, C.; Taylor, L.; Cox, K. Muscarinic agonists and antagonists in the treatment of Alzheimer's disease. Il Farmaco, 2001, 56, 247-250.
10. Bymaster, F.P.; Whitesitt, C.A.; Shannon, H.E.; DeLapp, N.; Ward, J.S.; Calligaro, D.O.; Shipley, L.A.; Buelke-Sam, J.L.; Bodick, N.C.; Farde, L. Sheardown, M.J.; Olesen, P.H.; Hansen, K.T.; Suzdak, P.D.; Swedberg, M.D.B.; Sauerberg, P.; Mitch, C.H. Xanomeline: A selective muscarinic agonist for the treatment of Alzheimer’s disease. Drug Dev. Res., 1997, 40, 158-170.
11. Bodick, N.C.; Offen, W.W.; Levey, A.I.; Cutler, N.R.; Gauthier, S.G.; Satlin, A.; Shannon, H.E.; Tollefson, G.D.; Rasmussen, K.; Bymaster, F.P.; Hurley, D.J.; Potter, W.Z.; Paul, S.M. Effects of Xanomeline, a selective muscarinic receptor agonist, on cognitive function and behavorial symptoms in Alzheimer Disease. Arch. Neurol., 1997, 54, 465-473.
12. Shekhar, A.; Potter, W.Z.; Lightfoot, J.; Lienemann, J. Dube, S.; Mallinckrodt, C.; Bymaster, F.P.; McKinzie, D.L.; Felder, C.C. Selective muscarinic receptor agonist Xanomeline as a novel treatment approach for schizophrenia. Am. J. Psychiatry, 2008, 165, 1033-1039.
13. Wess, J. Allosteric binding sites on muscarinic receptors. Mol. Pharmacol., 2005, 68, 1506-1509.
14. Conn, P.J; Christopoulus, A.; Lindsley, C.W. Allosteric modulators of GPCRs: a novel approach for the treatment of CNS disorders. Nat. Rev. Drug Disc., 2009, 8, 41-54.
15. Spalding, T.A.; Trotter, C.; Skjaerbaek, N.; Messier, T.L.; Currier, E.A.; Burstein, E.S.; Li, D.; Hacksell, U.; Brann, M.R. Discovery of an ectopic activation site on the M1 muscarinic receptor. Mol. Pharmacol., 2002, 61, 1297-1302.
16. Jones, C.K.; Brady, A.E.; Davis, A.A.; Xiang, Z.; Bubser, M.; Tantouwy, N.; Kane, A.S.; Bridges, T.M.; Kennedy, J.P.; Bradley, S.R.; Peterson, T.E.; Ansari, M.S.; Baldwin, R.M.; Kessler, RM.; Deutch, A.Y.; Lah, J.J.; Levey, A.I.; Lindsley, C.W.; Conn, P.J. Novel selective allosteric activator of the M1 muscarinic acetylcholine receptor regulates amyloid processing and produces antipsychotic-like activity in rats. J. Neurosci., 2008, 41, 10422-10433.
17. Digby, G.J.; Shirey, J.K.; Conn, P.J. Allosteric activators of muscarinic receptors as novel approaches for treatment of CNS disorders. Mol. BioSyst., 2010, 6, 1345-1354.
18. Conn, P.J.; Jones, C.K.; Lindsley, C.W. Subtype-selective allosteric modulators of the muscarinic receptors for the treatment of CNS disorders. Trends Pharmacol. Sci., 2009, 30, 148-155.
19. Kuduk, S.D.; Beshore, D.C. Novel M1 allosteric ligands: a patent review. Exp. Opin. Ther. Pat., 2012, 22, 1385-1398.
20. Davie, B.J.; Christopoulos, A.; Scammells, P.J. Development of M1 mAChR Allosteric and Bitopic Ligands: Therapeutics for the Treatment of Cognitive Deficits. ACS Chem. Neurosci., 2013, 4, 1026-1048.
21. Ma, L.; Seager, M.; Wittmann, M.; Jacobsen, M.; Bickel, D.; Burno, M.; Jones, K.; Kuzmick-Graufelds, V.; Xu, G.; Pearson, M.; McCampbell, A.; Gaspar, R.; Shughrue, P.; Danziger, A.; Regan, C.; Flick, R.; Pascarella, D.; Garson, S.; Doran, S.; Kreatsoulas, C.; Veng, L.; Lindsley, C.; Shipe, W.; Kuduk, S.D.; Sur, C.; Kinney, G.; Seabrook, G.; Ray, W.J. Selective activation of the M1 muscarinic acetylcholine receptor achieved by allosteric potentiation. Proc. Natl.Acad. Sci. USA, 2009, 106, 15950-19555.
22. Shirey, J.K.; Brady, A.E.; Jones, P.J.; Davis, A.A.; Bridges, T.M.; Kennedy, J.P.; Jadhav, S.B.; Menon, U.N.; Xiang, Z.; Watson, M.L.; Christian, E.P.; Doherty, J.J.; Quirk, M.C.; Snyder, D.H.; Lah, J.J.; Levey, A.I.; Nicolle, M.M.; Lindsley, C.W.; Conn, P.J. A selective allosteric potentiator of the M1 muscarinic acetylcholine receptor increases activity of medial prefrontal cortical neurons and restores impairments in reversal learning. J. Neurosci., 2009, 45, 14271-14286.
23. Chambon, C.; Jatzke, C.; Wegener, N.; Gravius, A.; Danysz, W. Using cholinergic M1 receptor positive allosteric modulators to improve memory enhancement of brain cholinergic communication. Eur. J. Pharm., 2012, 697, 73-80.
24. Yang, F.V.; Shipe, W.D.; Bunda, J.L.; Wisnoski, D.D.; Zhao, Z.; Lindsley, C.W.; Ray, W.J.; Ma, L.; Wittmann, M.; Seager, M.W.; Koeplinger, K.; Thompson, C.D.; Hartman, G.D. Parallel synthesis of N-biaryl quinolone carboxylic acids as selective M1 positive allosteric modulators Bioorg. Med. Chem. Lett., 2009, 19, 531-535.
25. Gould, R.G.; Jacobs, W.A. The synthesis of certain substituted quinolines and 5,6-benzoquinolines J. Am. Chem. Soc., 1939, 61, 2890-2896.
26. Conn, P.J.; Jones, C.K.; Lindsley, C.W. Subtype-selective allosteric modulators of the muscarinic receptors for the treatment of CNS Disorders. Trends Pharmacol. Sci., 2009, 30, 148-155.
27. Shirey, J.K.; Brady, A.E.; Jones, P.J.; Davis, A.A.; Bridges, T.M.; Kennedy, J.P.; Jadhav, S.B.; Menon, U.N.; Xiang, Z.; Watson, M.L.; Christian, E.P.; Doherty, J.J.; Quirk, M.C.; Snyder, D.H.; Lah, J.J.; Nicolle, M.M.; Lindsley, C.W.; Conn, P.J. A selective allosteric potentiator of the M1 muscarinic acetylcholine receptor increases activity of medial prefrontal cortical neurons and restores impairments in reversal learning J. Neurosci., 2009, 45, 14271-14286.
28. Bridges, T.M.; Kennedy, J.P.; Noetzel, M.J.; Breininger, M.L.; Gentry, P.R.; Conn, P.J.; Lindsley, C.W. Chemical lead optimization of a pan Gq mAChR M1, M3, M5 positive allosteric modulator (PAM) lead. Part II: Development of a potent and highly selective M1 PAM Biorg. Med. Chem. Lett., 2010, 20, 1972-1975.
29. Maurer, T.S.; DeBartolo, D.B.; Tess, D.A.; Scott, D.O. Relationship between exposure and nonspecific binding of thirty-three central nervous system drugs in mice Drug Metab. Dispos., 2005, 33, 175-181.
30. Kuduk, S.D.; DiPardo, R.M.; Di Marco, C.N.; Chang, R.K.; Murphy, K.L.; Ransom, R.W.; Harrell, C.M.; Reiss, D.R.; Tang, C.; Prueksaritanont, T.; Pettibone, D.J.; Bock, M.G. Bradykinin B1 antagonists: Biphenyl SAR studies in the cyclopropanecarboxamide series Bioorg. Med. Chem. Lett., 2007, 17, 3608–3612.
31. Kuduk, S.D.; Di Marco, C.N.; Cofre, V.; Pitts, D.R.; Ray, W.J.; Ma, L.; Wittmann, M.; Seager, M.; Koeplinger, K.A.; Thompson, C.D.; Hartman, G.D.; Bilodeau, M.T. Pyridine containing M1 positive allosteric modulators with reduced plasma protein binding Bioorg. Med. Chem. Lett., 2009, 19, 657-660.
32. Doan, K.M.; Humphreys, J.E.; Webster, L.O.; Wring, S.A.; Shampine, L.J.; Serabjit-Singh, C.J.; Adkinson, K.K.; Polli, J.W. Passive permeability and P-glycoprotein mediated efflux differentiate central nervous system (CNS) and non-CNS marketed drugs. J. Pharmacol. Exp. Ther., 2002, 303, 1029-1037.
33. Gottesman, M.M.; Pastan, I. Biochemistry of multidrug resistance mediated by the multidrug transporter Annu. Rev. Biochem., 1993, 62, 385-427.
34. Hitchcock, S.A. Structural modifications that alter the Pglycopprotein efflux properties of compounds. J. Med. Chem., 2012, 55, 4877-4895.
35. Di, L.; Rong, H.; Feng, B. Demystifying brain penetration in central nervous system drug discovery. J. Med. Chem., 2013, 56, 2-12.
36. Kuduk, S.D.; Di Marco, C.N.; Cofre, V.; Pitts, D.R.; Ray, W.J.; Ma, L.; Wittmann, M.; Seager, M.; Koeplinger, K.A.; Thompson, C.D.; Hartman, G.D.; Bilodeau, M.T. N-Heterocyclic Derived M1 Positive Allosteric Modulators. Bioorg. Med. Chem. Lett., 2010, 20, 1334-1337.
37. Kuduk, S.D.; Di Marco, C.N.; Chang, R.K.; Ray, W.J.; Ma, L.; Wittmann, M.; Seager, M.; Koeplinger, K.A.; Thompson, C.D.; Hartman, G.D.; Bilodeau, M.T. Fused heterocyclic M1 positive allosteric modulators. Bioorg. Med. Chem. Lett., 2011, 20, 2769–2772.
38. Yang, F.V.; Shipe, W.D.; Bunda, J.L.; Wisnoski, D.D.; Zhao, Z.; Barrow, J.C.; Ray, W.J.; Ma, L.; Wittmann, M.; Seager, M.W.; Koeplinger, K.; Thompson, C.D.; Hartman, G.D.; Lindsley, C.W. Parallel synthesis of N-biaryl quinolone carboxylic acids as selective M1 positive allosteric modulators. Bioorg. Med. Chem. Lett., 2010, 20, 531-536.
39. Kuduk, S.D.; DiPardo, R.M.; Beshore, D.C.; Ray, W.J.; Ma, L.; Wittmann, M.; Seager, M.; Koeplinger, K.A.; Thompson, C.D.; Hartman, G.D.; Bilodeau, M.T. Hydroxy cycloalkyl fused pyridone carboxylic acid M1 positive allosteric modulators. Bioorg. Med. Chem. Lett., 2010, 20, 2538-2541.
40. Beshore, D.C.; DiPardo, R.M.; Chang, R.K.; Di Marco, C.N.; Pitts, D.R.; Ray, W.J.; Ma, L.; Wittmann, M.; McCampbell, A.; Seager, M.A.; Koeplinger, K.A.; Thompson, C.D.; Hartman, G.D.; Bilodeau, M.T.; Kuduk, S.D. In vitro and in vivo evaluation of quinolone carboxylic acid-derived selective M1 receptor positive allosteric modulators. Society for Neuroscience, 2010, Poster 509, San Diego, CA
41. Kuduk, S.D.; Chang, R.K.; Di Marco, C.N.; Ray, W.J.; Ma, L.; Wittmann, M.; Seager, M.; Koeplinger, K.A.; Thompson, C.D.; Hartman, G.D.; Bilodeau, M.T. Identification of Quinolizidinone Carboxylic Acids as CNS Penetrant, Selective M1 Allosteric Muscarinic Receptor Modulators. ACS Med. Chem. Lett., 2010, 1, 263-267.
42. Kuduk, S.D.; Chang, R.K.; Di Marco, C.N.; Ray, W.J.; Ma, L.; Wittmann, M.; Seager, M.; Koeplinger, K.A.; Thompson, C.D.; Hartman, G.D.; Bilodeau, M.T. Quinolizidinone Carboxylic Acid Selective M1 Allosteric Modulators: SAR in the Piperidine Series. Bioorg. Med. Chem. Lett., 2011, 20, 1710-1715.
43. Kuduk, S.D.; Chang, R.K.; Di Marco, C.N.; Pitts, D.R.; Greschock, T.J.; Ma, L.; Wittmann, M.; Seager, M.; Koeplinger, K.A.; Thompson, C.D.; Hartman, G.D.; Bilodeau, M.T.; Ray, W.J. Discovery of a Selective Allosteric M1 Receptor Modulator with Suitable Development Properties Based on a Quinolizidinone Carboxylic Acid. Scaffold J. Med. Chem., 2011, 13, 4773-4780.
44. Uslaner, J.M.; Eddins, D.M.; Puri, V.; Cannon, C.E.; Sutcliff, J.; Chew, C.S.; Pearson, M.; Vivian, J.A.; Chang, R.K.; Kuduk, S.D.; Wittmann, M. The Muscarinic M1 Receptor Positive Allosteric Modulator PQCA Improves Cognitive Measures in Rat, Cynomolgus Macaque, and Rhesus Macaque. Psychopharmacology, 2013, 1, 21-30.
45. Wood, M.R.; Hopkins, C.R.; Brogan, J.T.; Conn. P.J.; Lindsley, C.W. Molecular switches on mGluR allosteric ligands that modulate modes of pharmacology. Biochemistry, 2011, 50, 2403-2410.
46. Lamb, J.P.; Engers, D.W.; Niswender, C.M.; Rodriguez, A.L.; Venable, D.F.; Conn, P.J.; Lindsley, C.W. Discovery of molecular switches within the ADX-47273 mGlu5 PAM scaffold that modulate modes of pharmacology to afford potent mGlu5 NAMs, PAMs, and partial antagonists Biorg. Med. Chem. Lett., 2011, 21, 2711-2714.
47. Leach, K.; Sexton, P.M.; Christopoulos, A. Allosteric GPCR modulators: taking advantage of permissive receptor pharmacology. Trends Pharmacol. Sci., 2007, 28, 382-389.
48. Mistry, S.N.; Valant, C.; Sexton, P.M.; Capuano, B.; Christopoulos, A.; Scammells, P.J. Synthesis and pharmacological profiling of Benzyl Quinolone Carboxylic Acid (BQCA) as Allosteric Modulators of the M1 Muscarinic Receptor. J. Med. Chem., 2013, 27, 5151-5172.
49. Conn, P.J.; Kuduk, S.D.; Doller, D. Drug Design Strategies for GPCR Allosteric Modulators. Ann. Rep. Med. Chem., 2012, 47, 441-457.